Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!
Data: Harris Poll; Chart: Axios Visuals

A majority of Americans now, once again, say the worst of the pandemic is yet to come, per new Harris polling provided exclusively to Axios.

Why it matters: We took a brief hiatus from worrying about the pandemic, but the Delta variant and the response to it appear to have sent us back to a dark place.

What they're saying: “It’s clear we are still far from ‘Mission Accomplished’ on COVID," said Harris Poll CEO John Gerzema.

  • On June 6th, when vaccines were widely available, more than three-quarters of respondents said they thought that the worst is behind us.
  • Today only 46% of respondents feel the same way — a drop of 10 points from last week alone.

Reality check: The pessimists are probably right, but Americans won't all feel Delta's effect equally.

  • The unvaccinated remain at much higher risk of infection and severe disease than people who have received their shots.

Go deeper

Sep 15, 2021 - Health

Pfizer says data suggests COVID vaccine boosters are warranted

A nurse administering a booster shot of Pfizer's COVID-19 vaccine on Aug. 19 in Pasadena, Calif. Photo: Robyn Beck/AFP via Getty Images

Pfizer told the FDA Wednesday that data from its clinical trials suggests a third shot of its coronavirus vaccine may be necessary six months after the second dose because of waning efficacy.

Why it matters: The FDA's advisory committee on Friday is expected to review Pfizer's clinical trials and other supporting and conflicting data on coronavirus booster shots and make recommendations on whether more Americans 16 years and older should receive an extra dose.

Updated 15 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Vaccines: Los Angeles County to require vaccination proof at indoor bars — France suspends 3,000 unvaccinated health workers without pay — Moderna suggests booster shots, citing clinical data.
  2. Health: 1 in 500 Americans has died — Cases are falling, but deaths are rising — Study: Gaps in data on Native Hawaiians, Pacific Islanders alarming amid COVID.
  3. Politics: Gottlieb says CDC hampered U.S. response — 26 states have limited state or local officials' public health powers — Axios-Ipsos poll: 60% of voters back Biden vaccine mandates.
  4. Education: Denver looks to students to close Latino vaccination gap — Federal judge temporarily blocks Iowa's ban on mask mandates in schools — Massachusetts activates National Guard to help with school transportation.
  5. Variant tracker: Where different strains are spreading.
Sep 15, 2021 - Science

Moderna suggests booster shots, citing clinical data

A box of the Moderna COVID-19 vaccine in Indonesia. Photo: Algi Febri Sugita/SOPA Images/LightRocket via Getty Images

Moderna vaccine's efficacy declines a year after it's administered, compared to protection seen in recently inoculated individuals, the vaccine maker announced Wednesday.

Driving the news: Moderna made its case for supporting booster shots, citing clinical trial data that demonstrate breakthrough infections are less common among participants approximately eight months after receiving the first dose compared to approximately 13 months.